Author: Ravi Shankar

Helge Krogsbøl has decided to step down as Co-CEO of Heimstaden AB – Christian Fladeland, currently Co-CEO and Chief Investment Officer, is appointed CEO.

“Since joining Heimstaden in 2018, Helge has played a key role in transforming Heimstaden into a pan-European platform with more than 150,000 homes across nine markets. Following a successful streamlining of our operations, I support Helge’s decision to hand over the leadership to Christian, which is a strong and respected leader in the company with a clear strategic perspective. Together with our experienced management team, Christian will continue to strengthen Operations and Financials of Heimstaden,” says Chairperson Ivar Tollefsen.

“Christian and I have worked closely to expand Heimstaden’s footprint across Europe, and I am confident that Christian will continue our relentless effort to always strive for improvement, while preserving the values and culture that make this a unique company,” says Helge Krogsbøl.

“Helge has been a great colleague and has become a good friend who will be missed at Heimstaden. He leaves behind a strong organisation and a highly capable and competent management team. I look forward to continuing to develop the company together with them and all our talented colleagues across Heimstaden,” says Christian Fladeland.

Christian Fladeland is currently Co-CEO and Chief Investment Officer of Heimstaden. He has been part of the company’s management team since joining Heimstaden in 2019. Prior to joining Heimstaden, he was a partner at Danish commercial real estate advisory firm Sadolin & Albæk, today Colliers Denmark.

Contact

Cody Nelson, Investor Relations, +47 948 94 196, investor@heimstaden.com 
Ina Hesle, Media Relations, +47 908 01 506, media@heimstaden.com 

Heimstaden AB is a leading European residential real estate manager and investor with more than 155,000 homes across nine countries with a fair value of SEK 336 billion. We acquire, develop, and manage properties with an evergreen perspective. Heimstaden is listed on Nasdaq First North Growth Market. Read more at heimstadenab.com. Certified Adviser is DNB Carnegie Investment Bank AB.

Attachment

• Press Release Heimstaden AB Christian Fladeland new CEO 27102026

Further deleveraging, supported by privatisation sales, improved the interest coverage ratio (ICR). Operations delivered another quarter of solid progress, unmarked by increased uncertainty in the external environment. Interest rate volatility intensified during the quarter, weighing on transaction markets and property valuations. At the same time, higher capital costs and increased inflation expectations support the outlook for rental growth, underpinning the long-term fundamentals of our business.

Highlights for the quarter. Figures in brackets refer to the corresponding period the year before, unless otherwise stated. LTM refers to the last twelve months and captures Q4 2025 to Q3 2026:

• Like-for-like rental growth of 4.0% (4.5%) and rental income of SEK 4,036 million (3,982)
• The quarterly NOI margin improved to 77.2% (75.4%) and LTM NOI margin of 73.6% (72.1%)
• Heightened volatility in interest rates led to a -0.3% (0.2%) decrease in property values
• Privatisation sales, for the quarter, reached SEK 2,054 million (2,865) with 563 (615) residential units sold at a 24.3% (28.2%) premium to book value
• Real economic occupancy of 99.3% (98.6%)
• Net LTV of 46.2% (49.0%) and ICR of 2.3x (2.1x)
• S&P-defined LTV of 52.8% (54.3%) and S&P ICR of 1.8x (1.6x)
• Acquired both standing assets and forward purchase development assets in Denmark and the Netherlands at a total purchase price of approximately SEK 4,600 million
• Issued 2-year SEK 750 million and 3.5-year SEK 750 million green senior unsecured fixed rate and floating rate notes with coupons of 3.27% and STIBOR plus 87 basis points

Co-CEO Helge Krogsbøl comments: 

“Our teams delivered another quarter of solid operational progress, with rental growth ahead of core inflation, further improved occupancy, and a stronger margin. These results reflect the scalability of our operating platform and continued focus on improving the performance of our portfolio.”

Co-CEO Christian Fladeland comments: 

“Heightened interest rate volatility has weighed on sentiment in real estate investment markets. Nevertheless, the underlying fundamentals of residential rental housing continue to support our operating outlook and capacity for further deleveraging. Our key priority remains creating additional financial headroom and flexibility.”

Contact

Cody Nelson, Investor Relations, +47 948 94 196, investor@heimstaden.com
Ina Hesle, Media Relations, +47 908 01 506, media@heimstaden.com 

Heimstaden Bostad is a leading European residential real estate company with more than 155,000 homes across nine countries with a property value of SEK 336 billion. We acquire, develop, and manage properties with an evergreen perspective. Guided by our Scandinavian heritage and values Dare, Care, and Share – our 1,600 colleagues fulfil our mission to enrich and simplify our customers’ lives through Friendly Homes. More at heimstadenbostad.com

Attachments

• Press Release Heimstaden Bostad Q3 Results 27102026
• Heimstaden Bostad AB – Q3 2026 Report

Please see below information about transactions made under the third tranche of the 2026 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO).

Date on which the buy-back tranche was announced: 22 July 2026.

The duration of the buy-back tranche: 23 July to no later than 26 October 2026.

Further information on the tranche can be found in the stock market announcement on its commencement dated 22 July 2026, available here: https://newsweb.oslobors.no/message/678529

From 19 October to 22 October 2026, Equinor ASA has purchased a total of 518,500 own shares at an average price of NOK 435.0082 per share.

The third tranche of the 2026 share buy-back programme for Equinor ASA has now been completed.

Overview of transactions:

Date	Trading venue	Aggregated daily volume (number of shares)	Daily weighted average share price (NOK)	Total daily transaction value (NOK)
19 October	OSE	128,000	437.5732	56,009,369.60
	CEUX
	TQEX
20 October	OSE	130,000	435.7075	56,641,975.00
	CEUX
	TQEX
21 October	OSE	131,000	430.0386	56,335,056.60
	CEUX
	TQEX
22 October	OSE	129,500	436.7980	56,565,341.00
	CEUX
	TQEX
Total for the period	OSE	518,500	435.0082	225,551,742.20
	CEUX
	TQEX
Previously disclosed buy-backs under the tranche	OSE	8,238,107	398.4234	3,282,254,732.19
	CEUX
	TQEX
	Total	8,238,107	398.4234	3,282,254,732.19
Total buy-backs under the tranche (accumulated)	OSE	8,756,607	400.5897	3,507,806,474.39
	CEUX
	TQEX
	Total	8,756,607	400.5897	3,507,806,474.39

Following completion of the above transactions, Equinor ASA owns a total of 23,595,817 own shares, corresponding to 0.99% of Equinor ASA’s share capital, including shares under Equinor’s share savings programme (excluding shares under Equinor’s share savings programme, Equinor owns a total of 12,291,582 own shares, corresponding to 0.51% of the share capital).

This is information that Equinor ASA is obliged to make public pursuant to the EU Market Abuse Regulation and that is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Appendix: An overview of all transactions made under the buy-back tranche that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

Contact details:

Investor relations
Bård Glad Pedersen, senior vice president Investor Relations,
+47 918 01 791

Media
Sissel Rinde, vice president Media Relations,
+47 412 60 584

Attachment

• Detailed overview of transactions

EINDHOVEN, The Netherlands, Oct. 27, 2026 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announced that it will release its third-quarter 2026 financial results and host a webcast with a comprehensive business update on November 3, 2026.

The webcast, presented by CEO Dave Marver, will begin at 2:00 p.m. CET / 8:00 a.m. ET. To join, please register using this link. A replay of the webcast and supporting materials will be available at ir.onwd.com.

About ONWARD Medical

ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities. Building on decades of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed its proprietary ARC Therapy. It has subsequently been awarded 10 Breakthrough Device Designations from the FDA. The Company’s ARC-EX^® System is cleared for commercial sale in the US and Europe. The Company is also developing an investigational implantable system called ARC-IM^®, designed to address several unmet needs including blood pressure instability after spinal cord injury. It can also be paired with a brain-computer interface (BCI) and artificial intelligence (AI) to restore thought-driven movement.

Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD), and its US ADRs can be traded on OTCQX (ticker: ONWRY).

To learn more about ONWARD Medical’s commitment to partnering with the spinal cord injury community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit ONWD.com.

To be kept informed about the Company’s technologies, research studies, and the availability of therapies in your area, please complete this webform.

For Media Inquiries:
Sébastien Cros, VP Communications
media@onwd.com

For Investor Inquiries:
investors@onwd.com

Disclaimer

Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited.

Investigational Products: ARC-IM and ARC-BCI are investigational and not available for commercial use. ARC-IM is limited by United States law to investigational use.

Paris, France – October 27, 2026

Q3 2026 financial results and conference call

Viridien will publish its third quarter 2026 results on Tuesday, November 3, after market close.

• The press release and presentation will be made available on www.viridiengroup.com at 5.45 pm (CET)
• An English-language conference call is scheduled at 6.00 pm (CET) on the same day

Participants must register for the conference call by clicking here to receive a dial-in number and PIN code. Participants may also join the live webcast by clicking here.

A replay of the conference call will also be available, for a period of 12 months, on the Company’s website www.viridiengroup.com.

About Viridien:

Viridien (www.viridiengroup.com) is an advanced technology, digital and Earth data company that pushes the boundaries of science for a more prosperous and sustainable future. With our ingenuity, drive and deep curiosity we discover new insights, innovations, and solutions that efficiently and responsibly resolve complex natural resource, digital, energy transition and infrastructure challenges. Viridien employs around 3,000 people worldwide and is listed as VIRI on the Euronext Paris SA (ISIN: FR001400PVN6).

Contacts

Investor Relations Alexandre Leroy Tel: + 33 6 85 18 44 31 E-Mail: ir@viridengroup.com

Media Relations Sara Pink-Zerling Tel: + 33 6 37 57 95 44 E-Mail: media.relations@viridiengroup.com

Attachment

• Publication of the Q3 2026 financial results on Tuesday November 3, 2026, after market close

Press release
Paris, 27 October 2026

Financial information at September 30, 2026

Orange maintains solid revenue growth in the third quarter and raises its full-year EBITDAaL growth target

• Revenue rose +3.6%¹ in the third quarter, driven by growth across all our geographies: Africa and Middle East (+14.2%), Europe 6² (+5.3%), Spain (+3.5%) and France (+0.5%).
• Robust retail services growth of +3.3%, supported by a strong commercial performance.
• EBITDAaL grew +4.6% (+4.8% over 9 months), enabling the Group to raise its 2026 Group EBITDAaL growth guidance to above +4.5%.
• eCAPEX decreased -2.5% in the quarter; the eCAPEX-to-revenue ratio standing at 14.8% over 9 months.
• Operating cash-flow (EBITDAaL – eCapex) significant increase by +8.8% over 9 months.

In millions of euros		3Q 2026	change comparable basis	change historical basis		9M 2026	change comparable basis	change historical basis
Revenues		12,191	3.6 %	22.0 %		33,138	3.5 %	11.0 %
EBITDAaL		4,140	4.6 %	20.4 %		10,268	4.8 %	12.7 %
eCAPEX		1,712	(2.5) %	16.7 %		4,893	0.8 %	9.0 %
EBITDAaL – eCAPEX		2,428	10.3 %	23.2 %		5,374	8.8 %	16.2 %

Note: Orange España (formerly MasOrange) was accounted for using the equity method for the first five months of 2026 and has been fully consolidated since June 2026.

“This third quarter confirms the strong momentum generated by our Trust the future plan. Revenue increased across all our geographies, driven by a robust commercial performance. Africa and Middle East continued its remarkable growth, while Europe, particularly Poland, delivered solid results.

We are continuing to implement our plan, with several developments in the third quarter: the launch of new offers in France, the integration of MasOrange now renamed Orange España, sustained growth of Orange Cyberdefense, and an extended SecNumCloud qualification for Orange Business’s cloud offerings.

In October, we signed a letter of intent with Deutsche Telekom, Telefónica and Vodafone to explore a joint bid for MSS spectrum allocation in Europe for mobile satellite services. This initiative supports the ambition to strengthen the sovereignty, security and resilience of Europe’s strategic infrastructure.

Building on sustained EBITDAaL growth of 4.8% in the first nine months of the year, we are raising our 2026 target to growth of more than 4.5%.

I would like to thank all our teams for their commitment and for driving our projects and transformation forward.”

Christel Heydemann, Orange group CEO

In the third quarter of 2026, the Group generated revenue of €12.2 billion, up 3.6%. All geographies contributed to this growth: Africa and Middle East (+14.2%), Europe 6 (+5.3%), Spain (+3.5%) and France (+0.5%). Retail services grew by +3.3%, reflecting solid commercial momentum, driven by remarkable growth in Africa and Middle East (+15.2%), the acceleration of convergent services in Europe 6 (+6.7%) and increase in retail services excluding PSTN³ in France (+1.1%).

The Group’s EBITDAaL reached €4.1 billion in the third quarter, up 4.6%, driven by accelerating revenue growth and continued operational efficiency initiatives. The strong EBITDAaL performance, with growth of 4.8% in the first nine months of the year, enables the Group to raise its 2026 growth guidance from above 4% to above 4.5%.

eCAPEX amounted to €1.7 billion in the third quarter, down 2.5%, and represented 14.8% of revenue over the first nine months of the year, well in line with the annual target of around 15%.

Operating cash-flow (EBITDAaL – eCapex) increased significantly by 10.3% in the third quarter, fueling growth to 8.8% over the first nine months of the year.

Commercial performance

The Group continues to expand its customer base, which exceeded 367 million accesses at the end of September 2026.

In thousand, at the end of the period			September 30 2026		September 30 2025 historical basis
Number of convergent customers			14 267		9 256
Number of mobile accesses (excluding MVNOs)			322 310		269 736
Number of fixed accesses			45 342		38 102
o/w	Very high‑speed broadband fixed accesses		24 423		15 981
The 2026 data includes accesses from Orange España (formerly MasOrange), fully consolidated in the Orange Group accounts since June 2026.

Joint bid to acquire SFR alongside Bouygues Telecom and Free–iliad Group
        
On 6 June 2026, Orange, alongside Bouygues Telecom and Free–iliad Group, announced the signature of a Memorandum of Understanding with Altice France to acquire SFR, France’s second-largest telecommunications operator.
While rulings are expected in proceedings brought by the works council within the Altice France group, Orange remains committed to constructive social dialogue, which is ongoing.
Expected closing in the second half of 2027 remains unchanged, subject to regulatory approvals.

Guidance

The Group raises its EBITDAaL target, and confirms all the other financial elements of the guidance for 2026:

• EBITDAaL growth exceeding +4.5% (previously above +4%)
• eCAPEX-to-revenue ratio of approximately 15%
• Organic cash flow⁴ reaching around €4.3 billion (target raised in Q2 2026)
• Net debt/EBITDAaL ratio with a medium-term target of around 2x

For the 2026 fiscal year, Orange has set a dividend of €0.79 per share, payable in 2027⁵.

Orange will make an interim dividend cash payment for 2026 of €0.30 per share on December 3, 2026.

___________________________________________________________________________________________

The Board of Directors of Orange SA met on 26 October 2026 and reviewed the consolidated results as of 30 September 2026.

Further information on the Group’s results and performance indicators is available on Orange’s website Financial and extra-financial information | Orange.

Review by operating segment

France

In millions of euros		3Q 2026	change comparable basis	change historical basis		9M 2026	change comparable basis	change historical basis
Revenue		4,363	0.5 %	0.5 %		13,034	1.0 %	1.0 %
Retail services (B2C+B2B)		2,822	(0.0)%	(0.0)%		8,432	0.0 %	0.0 %
Convergence		1,381	1.7 %	1.7 %		4,107	2.1 %	2.1 %
Mobile-only		558	(3.0)%	(3.0)%		1,673	(2.8)%	(2.8)%
Fixed-only		883	(0.8)%	(0.8)%		2,653	(1.2)%	(1.2)%
Wholesale		980	(4.1)%	(4.1)%		3,034	(0.4)%	(0.4)%
Equipment sales		392	16.1 %	16.1 %		1,024	9.2 %	9.2 %
Other revenue		170	6.7 %	6.7 %		545	9.8 %	9.8 %

Revenue growth driven by strong retail services momentum with record net adds

Revenue in France reached €4,363 million in the third quarter of 2026, up +0.5%. Retail services excluding PSTN continued to grow at +1.1%, supported by our effective value and multi-service strategy. Equipment sales increased +16.1%, driven by strong demand for premium devices. Wholesale services continued to decline at the expected pace (-4.1%).

In the third quarter 2026, Orange France achieved record net adds in mobile (+146k), fixed broadband (+78k) and, particularly, convergence (+57k).

Fixed-only broadband ARPO increased (+€0.4 yoy to €38.7), driven by growth in multi-service offers and upselling initiatives. Mobile-only ARPO declined (-€0.8 yoy to €15.9) due to the competitive market environment, partly reflected in convergent ARPO (-€0.3 yoy to €78.3).

Customer satisfaction and innovation remain key differentiators for Orange, which maintains its leading position in Net Promoter Score with a 9-point lead over the second-ranked operator and continued to introduce new offers and services for its customers this quarter.

These strong results confirm our ambition to deliver “stable +” EBITDAaL in 2026.

Spain

In millions of euros		3Q 2026	change comparable basis	change historical basis		4M 2026	change comparable basis	change historical basis
Revenue		1,910	3.5 %	–		2,558	3.1 %	–
Retail services (B2C+B2B)		1,368	(1.3)%	–		1,830	(1.0)%	–
Convergence		749	(3.9)%	–		995	(4.4)%	–
Mobile-only		402	(4.1)%	–		498	(3.4)%	–
Fixed-only		161	0.6 %	–		256	0.9 %	–
IT & Integration services		56	104.2 %	–		81	115.1 %	–
Wholesale		179	3.6 %	–		231	3.7 %	–
Equipment sales		353	28.0 %	–		472	28.5 %	–
Other revenue		10	(14.4)%	–		26	(41.1)%	–

Note: Orange España (formerly MasOrange) was accounted for using the equity method for the first five months of 2026 and has been fully consolidated since June 2026.

Improving trend in service revenue

MasOrange became Orange España on 23 September. This marks a new chapter for Orange, strengthening the brand’s visibility and reaffirming its long-term commitment to the country.

In the third quarter of 2026, revenue in Spain reached €1,910 million, up +3.5%, driven by equipment sales (+28%) and wholesale services (+3.6%). The retail services revenue trend improved compared to the previous quarter.

Commercial momentum continued to improve, with positive net adds in fixed broadband (+7k), mobile (+12k) and new services (+169k). Convergent ARPO rose to €53.1 (+€0.2 yoy).

New B2B wins with major ports, large cities and players in the security sector further strengthen our position as a leading provider of trusted private networks in Spain.

The target of low-single-digit EBITDAaL growth in Spain in the second half of 2026 is confirmed.

Africa & Middle East

In millions of euros		3Q 2026	change comparable basis	change historical basis		9M 2026	change comparable basis	change historical basis
Revenue		2,401	14.2 %	14.0 %		6,976	14.0 %	11.7 %
Retail services (B2C+B2B)		2,206	15.2 %	15.0 %		6,388	14.5 %	12.3 %
Mobile-only		1,868	15.0 %	14.9 %		5,412	14.7 %	12.5 %
Fixed-only		301	12.3 %	11.9 %		864	10.9 %	8.8 %
IT & Integration services		38	53.8 %	54.0 %		111	38.4 %	34.6 %
Wholesale		148	(1.7)%	(2.6)%		464	5.3 %	2.5 %
Equipment sales		31	19.9 %	19.2 %		82	16.2 %	12.9 %
Other revenue		16	67.0 %	67.0 %		43	41.7 %	37.0 %

Record double-digit growth

Africa and Middle East confirmed their role as a growth driver for the Group, with third-quarter revenue of €2,401 million, a record increase of +14.2%.

All countries contributed to this outstanding performance driven by retail services (+15.2%) and supported by strong momentum across all key growth drivers: mobile data revenue (+20.2%), fixed broadband (+15.0%), Orange Money (+14.6%) and across B2B activities (+23.1%).

These results reflect an excellent commercial performance, with strong growth in our customer base as of 30 September 2026: 180 million mobile customers (+4.2% yoy), 98 million 4G customers (+11.0%), 54 million Orange Money customers (+21.8%) and nearly 5.4 million fixed broadband customers (+15.7%). Average mobile-only ARPO rose by +7.5% in the third quarter.

These achievements confirm the outlook for double-digit EBITDAaL growth in 2026.

Europe 6

In millions of euros		3Q 2026	change comparable basis	change historical basis		9M 2026	change comparable basis	change historical basis
Revenue		1,896	5.3 %	4.5 %		5,502	4.5 %	3.6 %
Retail services (B2C+B2B)		1,387	5.2 %	4.4 %		4,044	4.2 %	3.8 %
Convergence		406	6.7 %	6.0 %		1,199	6.7 %	6.3 %
Mobile-only		552	0.5 %	(0.1)%		1,631	(0.1)%	(0.5)%
Fixed-only		232	(4.4)%	(5.1)%		706	(3.5)%	(3.9)%
IT & Integration services		196	34.9 %	33.4 %		507	29.6 %	28.8 %
Wholesale		215	(2.0)%	(2.7)%		627	1.7 %	1.3 %
Equipment sales		276	10.4 %	9.6 %		771	7.1 %	6.7 %
Other revenue		18	42.1 %	41.2 %		60	22.9 %	(17.0)%

Strong revenue growth, with convergent offers gaining momentum

In the third quarter, Europe 6 generated revenue of €1,896 million, up a solid +5.3%. Retail services increased +5.2%, driven by strong commercial momentum in convergent offers (+6.7%) and exceptional IT & Integration services performance, mainly in Poland and Romania.

Europe 6 recorded strong net adds in the third quarter across mobile (+145k), convergence (+27k) and fiber (+71k).

The performance in Poland was particularly strong with convergent ARPO up +5.0% yoy, while quarterly revenue increased +7.9%. Moreover, the completion of the acquisition of Nexera acquisition by our FiberCo, co-controlled with APG, strengthens the joint venture’s growth prospects and expands Orange Poland’s fiber footprint.

Based on these very strong third-quarter results, the Europe 6 EBITDAaL growth outlook of mid-single-digit growth in 2026 is confirmed.

Orange Business

In millions of euros		3Q 2026	change comparable basis	change historical basis		9M 2026	change comparable basis	change historical basis
Revenue		1,717	(2.5)%	(1.7)%		5,219	(2.9)%	(4.0)%
Fixed-only		607	(10.0)%	(8.8)%		1,865	(9.2)%	(9.2)%
Voice		145	(12.5)%	(12.4)%		444	(12.5)%	(12.7)%
Data		462	(9.1)%	(7.6)%		1,421	(8.2)%	(8.0)%
IT & Integration services		904	4.0 %	4.6 %		2,707	2.2 %	(0.3)%
Mobile		206	(5.2)%	(5.2)%		647	(3.5)%	(3.5)%
Mobile-only		162	(4.5)%	(4.5)%		490	(5.3)%	(5.3)%
Wholesale		4	(17.6)%	(17.6)%		11	(17.6)%	(17.6)%
Equipment sales		40	(7.0)%	(7.0)%		147	4.3 %	4.3 %

Accelerating transformation in a complex environment

Orange Business generated revenue of €1,717 million in the third quarter of 2026, down -2.5%, as the macroeconomic environment weighed on activity.

Against this backdrop, Orange Business continues to execute its transformation plan, which aims to accelerate the go-to-market of its AI and trusted cloud solutions, particularly to the defense and security sectors, while accelerating efficiency notably through AI and its international partnership with Tech Mahindra.

In the third quarter, Orange Business obtained a new SecNumCloud qualification, strengthening its trusted cloud portfolio. Orange Business was also selected to provide the backbone of the European Union’s network for trusted data exchange.

Orange Cyberdefense accelerated its growth to +12.2% over the first nine months of the year, reaching €1 billion in revenue.

Orange Cyberdefense is commercializing its Dynamic SOC platform in nine European countries and has deployed Qevlar AI solution across 36 Security Operations Centers, reducing threat detection and analysis times.

However, the complex market environment is weighing on EBITDAaL improvement trend.

TOTEM

In millions of euros		3Q 2026	change comparable basis	change historical basis		9M 2026	change comparable basis	change historical basis
Revenue		173	(2.9)%	(2.9)%		532	(1.7)%	(1.7)%
Wholesale		173	(2.9)%	(2.9)%		532	(1.7)%	(1.7)%
Other revenue		–	–	–		–	–	–

TOTEM’s revenue was €173 million in the third quarter, down -2.9%. Growth in revenue from hosting third-party operators (+10.7%) only partly offset the decline in low-margin survey activities. The tenancy ratio has now reached 1.5x, which was the target set for 2026 when TOTEM was launched.

International Carriers & Shared Services

In millions of euros		3Q 2026	change comparable basis	change historical basis		9M 2026	change comparable basis	change historical basis
Revenue		321	5.2 %	5.2 %		910	1.2 %	1.0 %
Wholesale		196	(1.9)%	(1.9)%		569	(3.7)%	(3.9)%
Other revenue		125	18.9 %	18.5 %		341	10.7 %	10.3 %

Revenue from International Carriers & Shared Services increased +5.2% in the third quarter, mainly driven by Orange Marine’s activities.

Calendar of upcoming events

18 February 2027        – Publication of Full-Year 2026 financial results

Contacts

press: Eric Fohlen-Weill eric.fohlen-weill@orange.com Tom Wright tom.wright@orange.com Fatima Rahil fatima.rahil@orange.com

financial communication: (analysts and investors) Constance Gest constance.gest@orange.com Aurélia Roussel aurelia.roussel@orange.com Hong Hai Vuong honghai.vuong@orange.com Clarisse Quellec clarisse.quellec@orange.com Damien Levesque damien.levesque@orange.com

Disclaimer

This press release contains forward-looking statements about Orange’s financial situation, results of
operations and strategy. Forward-looking statements are statements that are not historical facts.
These statements include, without limitation, projections and estimates and their underlying
assumptions, statements regarding plans, objectives, intentions and expectations with respect to
future financial results and other events, prospects and statements regarding future performance.
Although we believe these statements are based on reasonable assumptions, they are subject to
numerous risks, uncertainties and assumptions, including matters not yet known to us or not currently
considered material by us, and which could cause actual results and developments to differ materially
from those expressed in, or implied or projected by, such forward-looking statements. There can be
no assurance that anticipated events will occur or that the objectives set out will actually be achieved.
More detailed information on the potential risks, uncertainties and assumptions that could affect our
financial results include those described or identified in any public documents filed with the French
Financial Markets Authority (AMF) by Orange, including the Universal Registration Document filed on
2 April 2026 with the AMF. In light of these risks, uncertainties and assumptions, you should not
place undue reliance on any forward looking statements contained herein. Forward-looking statements
speak only as of the date they are made. Other than as required by law, Orange does not undertake
any obligation to update them in light of new information, future developments or any other reason.

Appendix 1: financial key indicators

Quarterly data

In millions of euros		3Q 2026	3Q 2025 comparable basis	3Q 2025 historical basis	variation comparable basis	change historical basis
Revenues		12,191	11,771	9,993	3.6 %	22.0 %
France		4,363	4,341	4,341	0.5 %	0.5 %
Spain		1,910	1,846	–	3.5 %	–
Europe 6		1,896	1,801	1,813	5.3 %	4.5 %
Africa & Middle-East		2,401	2,101	2,106	14.2 %	14.0 %
Orange Business		1,717	1,760	1,747	(2.5)%	(1.7)%
Totem		173	179	179	(2.9)%	(2.9)%
International Carriers & Shared Services		321	305	305	5.2 %	5.2 %
Intra-Group eliminations		(590)	(562)	(498)
EBITDAaL (1)		4,140	3,958	3,437	4.6 %	20.4 %
As % of revenues		34.0 %	33.6 %	34.4 %	0.3 pt	(0.4 pt)
eCAPEX		1,712	1,756	1,466	(2.5)%	16.7 %
As % of revenues		14.0 %	14.9 %	14.7 %	(0.9 pt)	(0.6 pt)
EBITDAaL – eCAPEX		2,428	2,202	1,971	10.3 %	23.2 %
(1) EBITDAaL presentation adjustments are described in Appendix 2.

30 September data

In millions of euros		9M 2026	9M 2025 comparable basis	9M 2025 historical basis	variation comparable basis	change historical basis
Revenues		33,138	32,014	29,846	3.5 %	11.0 %
France		13,034	12,910	12,910	1.0 %	1.0 %
Spain		2,558	2,481	–	3.1 %	–
Europe 6		5,502	5,266	5,309	4.5 %	3.6 %
Africa & Middle-East		6,976	6,120	6,245	14.0 %	11.7 %
Orange Business		5,219	5,374	5,438	(2.9)%	(4.0)%
Totem		532	541	541	(1.7)%	(1.7)%
International Carriers & Shared Services		910	898	901	1.2 %	1.0 %
Intra-Group eliminations		(1,593)	(1,577)	(1,498)
EBITDAaL (1)		10,268	9,793	9,112	4.8 %	12.7 %
As % of revenues		31.0 %	30.6 %	30.5 %	0.4 pt	0.5 pt
eCAPEX		4,893	4,855	4,489	0.8 %	9.0 %
As % of revenues		14.8 %	15.2 %	15.0 %	(0.4 pt)	(0.3 pt)
EBITDAaL – eCAPEX		5,374	4,938	4,623	8.8 %	16.2 %
(1) EBITDAaL presentation adjustments are described in Appendix 2.

NB : Orange España (formerly MasOrange) is accounted for using the equity method during the first five months of 2026 and is fully consolidated from June 2026 onward.

Appendix 2: adjusted data to income statement items

Quarterly data

		3Q 2026				3Q 2025 historical basis
In millions of euros		Adjusted data	Presentation adjustments	Income statement		Adjusted data	Presentation adjustments	Income statement
Revenues		12,191	–	12,191		9,993	–	9,993
External purchases		(5,323)	(5)	(5,328)		(3,986)	(0)	(3,986)
Other operating income		227	–	227		223	–	223
Other operating expense		(129)	(36)	(166)		(73)	(7)	(80)
Labor expenses		(2,017)	(1)	(2,017)		(1,950)	14	(1,936)
Operating taxes and levies		(391)	(1)	(393)		(319)	1	(318)
Gains (losses) on disposal of fixed assets, investments and activities		na	39	39		na	22	22
Restructuring costs		na	(46)	(46)		na	(21)	(21)
Depreciation and amortization of financed assets		(9)	–	(9)		(29)	–	(29)
Depreciation and amortization of right-of-use assets		(341)	–	(341)		(359)	(0)	(359)
Impairment of right-of-use assets		1	2	4		–	–	–
Interest expenses on liabilities related to financed assets		(1)	1	na		(3)	3	na
Interest expenses on lease liabilities		(68)	68	na		(59)	59	na
EBITDAaL		4,140	20	na		3,437	72	na
Significant litigation		(6)	6	na		1	(1)	na
Specific labor expenses		(0)	0	na		14	(14)	na
Fixed assets, investments and business portfolio review		39	(39)	na		22	(22)	na
Restructuring program costs		(45)	45	na		(21)	21	na
Acquisition and integration costs		(36)	36	na		(7)	7	na
Interest expenses on liabilities related to financed assets		na	(1)	(1)		na	(3)	(3)
Interest expenses on lease liabilities		na	(68)	(68)		na	(59)	(59)

30 September data

		9M 2026				9M 2025 historical basis
In millions of euros		Adjusted data	Presentation adjustments	Income statement		Adjusted data	Presentation adjustments	Income statement
Revenues		33,138	–	33,138		29,846	–	29,846
External purchases		(13,813)	(5)	(13,819)		(11,965)	1	(11,964)
Other operating income		725	–	725		633	–	633
Other operating expense		(462)	(14)	(476)		(261)	(23)	(283)
Labor expenses		(6,338)	(43)	(6,381)		(6,264)	(1,598)	(7,862)
Operating taxes and levies		(1,672)	(14)	(1,685)		(1,525)	0	(1,524)
Gains (losses) on disposal of fixed assets, investments and activities		na	2,598	2,598		na	64	64
Restructuring costs		na	(118)	(118)		na	(184)	(184)
Depreciation and amortization of financed assets		(33)	–	(33)		(88)	–	(88)
Depreciation and amortization of right-of-use assets		(1,083)	–	(1,083)		(1,074)	2	(1,072)
Impairment of right-of-use assets		(1)	(36)	(37)		–	(37)	(37)
Interest expenses on liabilities related to financed assets		(3)	3	na		(9)	9	na
Interest expenses on lease liabilities		(190)	190	na		(182)	182	na
EBITDAaL		10,268	2,561	na		9,112	(1,584)	na
Significant litigation		36	(36)	na		(10)	10	na
Specific labor expenses		(39)	39	na		(1,606)	1,606	na
Fixed assets, investments and business portfolio review		2,598	(2,598)	na		64	(64)	na
Restructuring program costs		(155)	155	na		(208)	208	na
Acquisition and integration costs		(71)	71	na		(14)	14	na
Interest expenses on liabilities related to financed assets		na	(3)	(3)		na	(9)	(9)
Interest expenses on lease liabilities		na	(190)	(190)		na	(182)	(182)

Appendix 3: economic CAPEX to investments in property, plant and intangible investment

In millions of euros		3Q 2026	3Q 2025 historical basis		9M 2026	9M 2025 historical basis
Investments in property, plant and equipment and intangible assets		2,012	1,707		5,542	5,261
Financed assets		(0)	(2)		(1)	(18)
Proceeds from sales of property, plant and equipment and intangible assets (excluding telecommunication licenses)		(135)	(92)		(467)	(223)
Telecommunication licenses		(165)	(145)		(180)	(531)
eCAPEX		1,712	1,466		4,893	4,489

Appendix 4: key performance indicators

In thousand, at the end of the period					September 30 2026		September 30 2025 (historical basis)
Number of convergent customers					14,267		9,256
Number of mobile accesses (excluding MVNOs) (1)					322,310		269,736
o/w	Convergent customers mobile accesses				28,143		16,175
	Mobile only accesses				294,167		253,561
o/w	Contract customers mobile accesses				143,537		100,367
	Prepaid customers mobile accesses				178,773		169,369
Number of fixed accesses (2)					45,342		38,102
o/w	Fixed Retail accesses				34,249		26,815
	o/w	Fixed Broadband accesses			30,848		22,673
		o/w	Very high‑speed broadband fixed accesses		24,423		15,981
			Convergent customers fixed accesses		14,267		9,256
			Fixed accesses only		16,581		13,417
	o/w	Fixed Narrowband accesses			3,401		4,142
o/w	Fixed Wholesale accesses				11,093		11,288
Group total accesses (1+2)					367,652		307,838
2025 data is on a comparable basis and includes Orange España’s accesses (formerly MasOrange), fully consolidated in the Orange Group accounts since June 2026.

Key performance indicators (KPI) by country are presented in the “Orange investors data book Q3 2026” available on the Group’s website www.orange.com, under Finance/Results: https://www.orange.com/en/finance/information-financiere-et-extra-financiere

Appendix 5: glossary

Key figures

Data on a comparable basis: data based on comparable accounting principles, scope of consolidation and exchange rates are presented for previous periods. The transition from data on an historical basis to data on a comparable basis consists of keeping the results for the period ended and then restating the results for the corresponding period of the preceding year for the purpose of presenting, over comparable periods, financial data with comparable accounting principles, scope of consolidation and exchange rate. The method used is to apply to the data of the corresponding period of the preceding year, the accounting principles and scope of consolidation for the period just ended as well as the average exchange rate used for the income statement for the period ended. Changes in data on a comparable basis reflect organic business changes. Data on a comparable basis is not a financial aggregate as defined by IFRS and may not be comparable to similarly-named indicators used by other companies.

Retail services (B2C + B2B): aggregation of revenues from (i) Convergent services, (ii) Mobile-only services, (iii) Fixed-only services and (iv) IT & integration services (see definitions). Retail Services (B2C+B2B) revenues include all revenues of a given scope excluding revenues from wholesale services, equipment sales and other revenues (see definitions).

EBITDAaL or “EBITDA after Leases”: operating income (i) before depreciation and amortization of fixed assets, effects resulting from business combinations, impairment of goodwill and fixed assets, share of profits (losses) of associates and joint ventures, (ii) after interest on debts related to financed assets and on lease liabilities, and (iii) adjusted for significant litigation, specific labor expenses, fixed assets, investments and businesses portfolio review, restructuring programs costs, acquisition and integration costs and, where appropriate, other specific elements. EBITDAaL is not a financial aggregate as defined by IFRS standards and may not be directly comparable to similarly-named indicators in other companies.

eCAPEX or “economic CAPEX”: investments in property, plant and equipment and intangible assets excluding telecommunication licenses, excluding dismantling assets, excluding financed assets and excluding assets acquired through a business takeover, minus the price of disposal of fixed assets (excluding telecommunication licenses). eCAPEX is not a financial performance indicator as defined by IFRS standards and may not be directly comparable to indicators referenced by similarly-named indicators in other companies.

Organic Cash Flow (telecoms activities): organic cash flow all-in from telecom activities corresponds, for the perimeter of the telecoms activities, to net cash provided by operating activities, minus (i) lease liabilities repayments and debts related to financed assets repayments, and (ii) purchases and sales of property, plant and equipment and intangible assets, net of the change in the fixed assets payables, (iii) excluding net telecommunication licenses paid and significant litigations paid or received. Organic cash flow (telecoms activities) is not a financial aggregate defined by IFRS and may not be comparable to similarly-named indicators used by other companies.

Free cash flow all-in (telecoms activities): free cash flow all-in from telecom activities corresponds to net cash provided by operating activities, minus (i) purchases and sales of property, plant and equipment and intangible assets, net of the change in the fixed assets payables, (ii) repayments of lease liabilities and on debts related to financed assets, and (iii) payments of coupons on subordinated notes. Free cash flow all-in from telecom activities is not a financial aggregate defined by IFRS and may not be comparable to similarly-named indicators used by other companies.

Adjusted consolidated net income: adjusted consolidated net income corresponds to the consolidated net income (i) before the effects of significant litigation, specific labor expenses, review of fixed assets, investments and business portfolio, restructuring programs costs, acquisition and integration costs, (ii) before the effects resulting from business combinations, (iii) before impairment losses recognized as part of asset impairment tests, (iv) before amortization and impairment losses of other intangible and tangible assets related to business combinations, (v) before amortization and impairment losses of the copper network dismantling asset in France, (vi) before the net income from discontinued operations and, (vii) where appropriate, before other significant specific items, (viii) restated for the effects of these adjustments on financial result and income taxes. Adjusted consolidated net income is not a financial aggregate defined by IFRS and may not be comparable to similarly-named indicators used by other companies.

Adjusted earnings per share (EPS) – Group share Net income – Basic: adjusted earnings per share are calculated by dividing (i) adjusted net income for the year attributable to the shareholders of the Group, after deduction of the effect of coupons on subordinated notes, (ii) by the weighted average number of ordinary shares outstanding during the period. Adjusted earnings per share is not a financial aggregate defined by IFRS and may not be comparable to similarly-named indicators used by other companies.

Earnings per share (EPS) – Group share Net income – Basic: basic earnings per share are calculated by dividing (i) net income for the year attributable to the shareholders of the Group, after deduction of the effect of coupons on subordinated notes, by (ii) the weighted average number of ordinary shares outstanding during the period.

Return On Capital Employed (ROCE): ROCE (Return On Capital Employed) from telecoms activities corresponds to Net Operating Profit After Tax (NOPAT) for the year ended (N) divided by Net Operating Assets (NOA) for the previous year (N-1).

Net Operating Profit After Tax (NOPAT) for the year ended (N) corresponds to operating profit (i) after interest on lease liabilities and on debts related to financed assets, and (ii) after income tax adjusted for the tax impact of financial income excluding interest on lease liabilities and on debts related to financed assets (tax charge calculated on the basis of the statutory tax rate applicable in France, the tax jurisdiction of the parent company Orange SA).

Net Operating Assets (NOA) for the previous year (N-1) correspond to (i) equity and (ii) financial liabilities and derivative liabilities (non‑current and current), excluding debts on financed assets, (iii) less financial assets and derivative assets (non‑current and current), cash and cash equivalents, including investments in Mobile Financial Services.

ROCE from telecoms activities is not a financial aggregate defined by IFRS and may not be comparable to similarly-named indicators used by other companies.

Performance indicators

Fixed retail accesses: number of fixed broadband accesses (FTTx, cable, xDSL, Fixed-4G / Fixed-5G, satellite and others) and fixed narrowband accesses (mainly PSTN).

Fixed wholesale accesses: number of fixed broadband and narrowband wholesale accesses operated by Orange.

Convergence

Convergent services: customer base and revenues from B2C Convergent retail offers, excluding equipment sales (see definition) defined as an offer combining at least a broadband access (FTTx, cable, xDSL, Fixed-4G / Fixed-5G with cell-lock…) and a mobile voice contract.

Convergent ARPO: average quarterly revenues per convergent offer (ARPO) calculated by dividing revenues from retail Convergent services offers invoiced to B2C customers generated over the past three months (excluding IFRS 15 adjustments) by the weighted average number of retail Convergent offers over the same period. ARPO is expressed by monthly revenues per convergent offer.

Mobile-only services

Mobile-only services: revenues from mobile offers (mainly outgoing calls: voice, SMS and data) invoiced to retail customers, excluding convergent services and equipment sales (see definitions). The customer base includes customers with a contract excluding retail convergence, machine-to-machine contracts and prepaid cards.

Mobile-only ARPO: average quarterly revenues from Mobile-only (ARPO) calculated by dividing revenues from Mobile-only retail services (excluding machine-to-machine and IFRS 15 adjustments) generated over the past three months by the weighted average of Mobile-only customers (excluding machine-to-machine) over the same period. The ARPO is expressed as monthly revenues per Mobile-only customer.

Fixed-only services

Fixed-only services: revenues from fixed retail offers, excluding B2C convergent offers and equipment sales (see definitions). It includes (i) fixed narrowband services (conventional fixed telephony), (ii) fixed broadband services, and (iii) business solutions and networks (with the exception of France, for which essential business solutions and networks are supported by Orange Business segment). For the Orange Business segment, Fixed-only service revenues include sales of network equipment related to the operation of voice and data services. The customer base consists of fixed narrowband and fixed broadband customers, excluding retail convergence customers.

Fixed-only Broadband ARPO: average quarterly revenues from Fixed-only Broadband (ARPO) calculated by dividing the revenue from Fixed-only Broadband retail services (excluding IFRS 15 adjustments) generated over the past three months by the weighted average of Fixed-only Broadband customers over the same period. ARPO is expressed as monthly revenues per Fixed-only Broadband customer.

IT & integration services

IT & Integration services: revenues from unified communication and collaboration services (Local Area Network and telephony, advising, integration and project management), hosting and infrastructure services (including Cloud Computing), applications services (customer relations management and other applications services), security services, video conferencing offers, machine-to-machine services (excluded connectivity) as well as sales of equipment related to the above products and services.

Wholesale

Wholesale: revenues from other carriers consists of (i) mobile services to other carriers including incoming traffic, visitor roaming, network sharing, national roaming and Mobile Virtual Network Operators (MVNOs), (ii) fixed services to other carriers including national networking, services to international carriers, high-speed and very high-speed broadband access (fibre access, unbundling of telephone lines and xDSL access sales) and the sale of telephone lines on the wholesale market, and (iii) equipment sales to other carriers.

Equipment sales

Equipment sales: revenues from all mobile and fixed equipment sales, excluding (i) equipment sales associated with the supply of IT & Integration services, (ii) sales of network equipment related to the operation of voice and data services in the Orange Business operating segment, (iii) equipment sales to other carriers, and (iv) equipment sales to dealers and brokers.

Other revenues

Other revenues: revenues including (i) equipment sales to external dealers and brokers, (ii) revenues from portals, online advertising and transverse activities of the Group, (iii) revenues from the removal of copper cables, and (iv) other miscellaneous revenues.

---

1 Unless otherwise stated, percentage changes are year-on-year performance versus the third quarter of 2025 on a comparable basis.
2 Following the creation of the Spain segment, the former “Europe” segment has been renamed “Europe 6” and includes Poland, Belgium, Luxembourg, Slovakia, Romania and Moldova.
3 Public Switched Telephone Network (PSTN)
4 Excluding costs related to Orange Bank discontinuation.
5 Subject to approval by the shareholders’ meeting.

Attachment

• PR_ORANGE_Q3_2026_EN_271026

EXOSENS DELIVERS +23.5% REVENUE GROWTH IN Q3 2026, DRIVEN BY STRONGER DEMAND AND FASTER-THAN-EXPECTED CAPACITY RAMP-UP

FULLY ON TRACK TO MEET UPGRADED 2026 OUTLOOK

HIGHLIGHTS

• Group revenue up +18.0% to €386.9 million in 9M 2026, including +14.4% LFL¹; clear acceleration in Q3 to +23.5%, including +20.5% LFL (vs. +11.4% LFL in H1), driven by strong commercial momentum and faster-than-expected capacity ramp-up
  • Amplification revenue up +15.5% in 9M 2026, with growth accelerating to +23.9% in Q3, driven by increasing global demand for high-performance image intensifier tubes in mission-critical night vision applications and faster-than-expected ramp-up of additional European production capacity
  • D&I revenue up +23.7% in 9M 2026, including +14.1% LFL, reflecting the increasing adoption of Exosens’ advanced imaging solutions across defense and surveillance markets, particularly in drone and counter-drone applications, alongside strong momentum in nuclear instrumentation, notably for next-generation SMRs
• Adjusted gross margin up +16.1% to €194.9 million in 9M 2026 (margin of 50.4%), with double-digit growth across Amplification (+14.1%) and D&I (+21.1%) segments
• Key milestone in the U.S.: first delivery order for 1,600 BiNOD systems, establishing Exosens as a supplier of complete night vision systems to the U.S. Army
• Strong operational execution: image intensifier tube production capacity on track to increase by 40% across Europe and the U.S. by 2027, with the first phase in Europe implemented and production ramping up faster than expected
• Scaling production of advanced imaging solutions: capacity set to triple for thermal cameras and double for cooled infrared cameras in 2026, to meet growing demand across drone, counter-drone and long-range surveillance applications

OUTLOOK

• Upgraded 2026 outlook confirmed: c.20% revenue growth and c.25% adjusted EBITDA growth at midpoint vs. 2025, implying further profitability improvement
  • Revenue in the range of €558 million to €570 million
  • Adjusted EBITDA in the range of €186 million to €192 million
  • Capital expenditure at around 9% of revenue (excluding capitalized R&D), driven by production capacity expansion in Europe and the United States

Press release, Mérignac (France), 27 October 2026 – Exosens (EXENS; FR001400Q9V2), a high-tech company focused on providing mission- and performance-critical amplification, detection and imaging technologies, today publishes its revenue and adjusted gross margin for the nine-month period ended 30 September 2026.

“Our nine-month performance demonstrates both strong commercial momentum and disciplined execution, with revenue growth reaching +18.0% over the period and accelerating to +23.5% in the third quarter. In Amplification, our additional European capacity for image intensifier tubes is ramping up ahead of plan, enabling us to serve strong demand for night vision solutions sooner than anticipated, while our first BiNOD delivery order marks a key step in building our presence in the U.S. market. In D&I, our advanced imaging technologies continue to gain traction in drone, counter-drone and long-range surveillance applications, as we scale production capacity to meet growing demand. Further progress in next-generation nuclear projects, particularly in SMRs, also reinforces our long-term growth prospects. Building on this sustained momentum, we are fully on track to meet our upgraded 2026 guidance,” said Jérôme Cerisier, CEO of Exosens.

Revenue up +18.0% in 9M 2026, with growth accelerating to +23.5% in Q3 2026, driven by strong commercial momentum and faster-than-expected capacity ramp-up

In € millions	9M 2025	9M 2026	Change (€m)	Change (%)	LFL (%)
Amplification	231.8	267.8	+36.0	+15.5%	+14.5%
Detection & Imaging	97.0	120.0	+23.0	+23.7%	+14.1%
Eliminations & Other	(0.9)	(0.9)	0.0	nm	nm
Total revenue	327.8	386.9	+59.1	+18.0%	+14.4%

Consolidated revenue amounted to €386.9 million in 9M 2026, up +18.0% (+€59.1 million) compared with €327.8 million in 9M 2025. This performance reflects the contributions from 2025 and 2026 acquisitions and strong like-for-like growth of +14.4%, driven by growing demand for mission-critical night vision and imaging solutions in defense and surveillance applications, alongside strong momentum in nuclear instrumentation. Growth accelerated markedly in Q3 2026 to +23.5%, including +20.5% like-for-like.

AMPLIFICATION

Amplification revenue amounted to €267.8 million (c.69% of Group sales) in 9M 2026, up +15.5% (+€36.0 million) compared with 9M 2025, including strong like-for-like growth of +14.5%. This sustained performance reflects increased image intensifier tube sales volumes and improved yields, together with the expected increase in NVLS’ contribution as the year progressed. Revenue growth accelerated to +23.9% in Q3 2026, from +11.6% in H1 2026, as additional European production capacity ramped up faster than expected.

Growing global defense spending and multi-year programs to modernize armed forces are accelerating the procurement of advanced night vision systems. Against this backdrop, Exosens builds on its position as the world’s leading supplier of high-performance, ITAR-free image intensifier tubes. The Group’s technological leadership and scalable industrial capabilities enable it to meet growing demand from NATO and allied armed forces.

Demand continued to exceed available production capacity in 9M 2026. In this context, Exosens’ ability to deliver higher volumes drove revenue growth, notably under major night vision procurement programs such as the OCCAR framework for the German and Belgian armed forces. Demand also continued to grow in other markets, particularly in Northern and Eastern Europe, as well as across several international markets. Adoption of 5G image intensifier technology also continued to expand among special forces in NATO countries.

Against this backdrop of accelerating global demand, Exosens continues to implement its investment plan to expand production capacity across Europe and the United States by 40% by 2027. The first phase in Europe was successfully implemented, with an extended operating schedule enabling production to run throughout August for the first time, while newly installed production equipment was commissioned. As a result, additional European production capacity ramped up faster than expected, enabling the Group to meet growing demand sooner than anticipated.

In the U.S., the rollout of the new manufacturing facility is underway, establishing scalable in-country production capacity to support future growth in the world’s largest single night vision market. Underscoring the effectiveness of its industrial strategy, Exosens reached a key milestone in August 2026 when its U.S. subsidiary, Photonis Defense, was awarded a first delivery order for 1,600 complete systems under the U.S. Army’s Binocular Night Observation Device (BiNOD) program, as part of the broader US$352.6 million Indefinite-Delivery/Indefinite-Quantity (IDIQ) contract announced in March 2026.

The order marks the transition from key testing and qualification to the Low-Rate Initial Production (LRIP) phase, laying the foundation for regular production of BiNOD systems in the United States. First product deliveries are expected by the end of 2026, with the bulk of deliveries scheduled throughout 2027. Photonis Defense will manufacture and test the complete BiNOD systems in the U.S., integrating Exosens’ high-performance image intensifier tubes.

DETECTION & IMAGING

D&I revenue reached €120.0 million (c.31% of Group sales) in 9M 2026, up +23.7% (+€23.0 million) compared with 9M 2025. This performance reflects the contributions from 2025 and 2026 acquisitions (Noxant, Phasics, Emberion) and strong like-for-like growth of +14.1%, driven by accelerating demand for advanced imaging solutions in defense and surveillance markets, particularly in drone and counter-drone applications, alongside strong momentum in nuclear instrumentation, notably for next-generation Small Modular Reactors (SMRs).

Defense & Surveillance

Imaging technologies are becoming central to modern defense operations, driven by two structural trends: (i) the growing integration of advanced optronic technologies into defense platforms, and (ii) the proliferation of drones and counter-drone systems that are becoming a core pillar of modern warfare and reshaping conventional defense operations. Against this favorable backdrop, Exosens is well positioned to capitalize on accelerating demand for advanced imaging solutions through its comprehensive portfolio of technologies enabling situational awareness, threat detection, identification and tracking, targeting, and long-range observation across a wide range of defense and surveillance applications.

Commercial momentum continued to build in 9M 2026, particularly in the fast-growing drone and counter-drone space, with Exosens’ advanced imaging solutions gaining further adoption among leading OEMs and autonomous defense systems developers. The Group’s understanding of UxV technological requirements and its support throughout the design-in phase help customers bring new systems to market faster. In addition, its agile supply chain and scalable industrial capabilities allow it to respond swiftly to accelerating market demand.

Surveillance markets also gained further momentum, driven by increasing investment in homeland security and counter-drone capabilities amid growing concerns over ground and airborne incursions. Demand was particularly strong for advanced imaging solutions used in long-range observation and counter-drone systems, with Exosens’ technologies increasingly adopted by leading OEMs and system integrators.

To meet growing demand, Exosens is implementing plans to triple production capacity for thermal cameras and double capacity for cooled infrared cameras in 2026. Together, these increases highlight the Group’s ability to anticipate evolving market requirements and scale production accordingly.

Commercial Markets

In Nuclear, demand for advanced detectors and instrumentation remained strong in 9M 2026, driven by growing investment in next-generation nuclear technologies, particularly SMRs. The nuclear market continues to benefit from rising demand for reliable, carbon-free power, driven by the rapid expansion of AI data centers and their substantial energy needs, reinforcing the long-term prospects for SMRs.

In the U.S., progress under the Department of Energy’s (DOE) Reactor Pilot Program highlights the accelerating deployment of next-generation reactors. Exosens supplied advanced neutron flux monitoring detectors and related technical expertise to Antares Nuclear and Valar Atomics, the developers behind the first two reactor designs to reach criticality under the program. These milestones are expected to lead to pre-series production orders in the near term and support long-term demand for Exosens’ nuclear instrumentation solutions across the U.S. market.

In Industrial Control, market conditions continued to show signs of recovery in 9M 2026. The expansion of AI infrastructure is expected to drive investment in semiconductor manufacturing and industrial automation, supporting long-term structural demand for Exosens’ advanced imaging technologies in semiconductor inspection, machine vision and real-time process monitoring. The Group is well positioned to benefit from these trends through its cutting-edge portfolio of infrared, UV and wavefront sensing technologies.

In Life Sciences, market conditions were mixed in 9M 2026. Global uncertainty weighed on scientific research and demand for microscopy components, while inventory drawdowns in mass spectrometry, now complete, softened demand for advanced detectors. Despite these temporary headwinds, market fundamentals remain favorable, driven by the shift towards higher-performance mass spectrometry systems. Rising private-sector R&D, notably in low-carbon materials and semiconductor testing, also drives long-term demand for the Group’s electron microscopy detectors. In this context, Exosens has secured design-ins for its technologies in several major projects, supporting growth in the coming years.

M&A

On 24 April 2026, Exosens completed the acquisition of Emberion, a Finland- and UK-based company specializing in the design and manufacturing of innovative infrared sensors leveraging patented quantum dot imaging technology. This acquisition strengthens Exosens’ advanced imaging portfolio with emerging quantum dot-based short-wave infrared sensors, supporting new opportunities in surveillance imaging, notably for drone-based systems, and in industrial applications such as semiconductor inspection.

Adjusted gross margin up +16.1% in 9M 2026

	9M 2025		9M 2026		Change
	In €m	% of sales	In €m	% of sales	In €m	In %
Amplification	121.8	52.5%	138.9	51.9%	+17.1	+14.1%
Detection & Imaging	46.1	47.6%	55.9	46.6%	+9.7	+21.1%
Eliminations & Other	0.1	nm	0.2	nm	+0.1	nm
Adjusted gross margin	168.0	51.2%	194.9	50.4%	+27.0	+16.1%

The Group’s adjusted gross margin reached €194.9 million in 9M 2026, up +16.1% (+€27.0 million) compared with €168.0 million in 9M 2025. The margin rate decreased by (85) basis points to 50.4% in 9M 2026 (versus 51.2% in 9M 2025). This reflects product mix effects in both segments, driven by the ramp-up of NVLS’ deliveries of complete night vision systems and strong revenue growth in defense imaging. Staffing costs at the U.S. facility also weighed on the margin rate. These effects were partly offset by higher image intensifier tube sales volumes and improved yields. In addition, the comparison base was particularly high in Q3 2025. The Group’s upgraded full-year guidance already factors in these operating effects.

The Amplification segment’s adjusted gross margin totaled €138.9 million in 9M 2026, up +14.1% (+€17.1 million) compared with 9M 2025. The margin rate decreased by (68) basis points to 51.9% in 9M 2026 (versus 52.5% in 9M 2025). As expected, the ramp-up of NVLS’ deliveries of complete night vision systems in Q3 2026, following a limited contribution in H1 2026, resulted in a less favorable product mix year on year, as NVLS, acquired in July 2025, contributed negligible revenue in 9M 2025. Staffing costs at the U.S. facility also weighed on the segment’s margin rate. These effects were partly offset by higher image intensifier tube sales volumes and improved yields. In addition, the comparison base was particularly high in Q3 2025, when the segment’s margin rate reached 54.9%, versus 50.5% for full-year 2025.

The Detection & Imaging segment’s adjusted gross margin amounted to €55.9 million in 9M 2026, up +21.1% (+€9.7 million) compared with 9M 2025. The margin rate declined by (103) basis points to 46.6% in 9M 2026 (versus 47.6% in 9M 2025). This margin contraction reflects a less favorable product mix, driven by the increased weight of fast-growing defense imaging products relative to higher-margin detectors, particularly those used in life sciences.

Upgraded 2026 outlook confirmed: c.20% revenue growth and c.25% adjusted EBITDA growth at midpoint vs. 2025, implying further profitability improvement

Building on sustained commercial momentum, reflected in the clear acceleration in like-for-like revenue growth in the third quarter, as well as continued disciplined execution, Exosens confirms its upgraded full-year 2026 guidance announced on 17 September 2026.

The Group expects:

• Revenue in the range of €558 million to €570 million;
• Adjusted EBITDA in the range of €186 million to €192 million;
• Capital expenditure at around 9% of revenue (excluding capitalized R&D expenses of around 3% of revenue), driven by production capacity expansion in Europe and the U.S.

Exosens will communicate its full-year 2027 guidance upon publication of the Group’s full-year 2026 results on 22 February 2027.

Financial Calendar

• 22/02/2027: Full-year 2026 results (before market opening).

About Exosens

Exosens is a high-tech company with more than 85 years of experience in the innovation, development, manufacturing and sale of high-end electro-optical technologies in the fields of amplification, detection and imaging. Today, it offers its customers detectors and imaging solutions such as digital cameras, ion, electron, neutron and gamma-ray detectors as well as image intensifier tubes. This enables Exosens to address complex challenges in extremely demanding environments by providing its customers with tailor-made solutions. Thanks to its sustained investment, Exosens is internationally recognized as a major innovator in optoelectronics, with production and R&D activities carried out at 13 sites across Europe and North America and more than 2,000 employees. Exosens is listed on compartment A of the regulated market of Euronext Paris (Ticker: EXENS – ISIN: FR001400Q9V2). Exosens is a member of the Euronext Tech Leaders segment and is also included in several indices, including SBF 120, CAC All-Tradable, CAC Mid 60, FTSE Total Cap and MSCI France Small Cap. For more information: www.exosens.com.

Investor Relations

Laurent Sfaxi, l.sfaxi@exosens.com

Media Relations

Brunswick Group, exosens@brunswickgroup.com

APPENDICES

Quarterly figures for 9M 2026

In € millions	Q1 2026	Q2 2026	H1 2026	Q3 2026	9M 2026
Amplification	88.1	88.2	176.3	91.5	267.8
Detection & Imaging	34.6	42.8	77.4	42.5	120.0
Eliminations & Other	(0.2)	(0.5)	(0.6)	(0.3)	(0.9)
Total revenue	122.6	130.5	253.1	133.8	386.9
Growth (%)	19.7%	11.4%	15.3%	23.5%	18.0%
Like-for-like (%)	12.5%	10.3%	11.4%	20.5%	14.4%

In € millions	Q1 2026	Q2 2026	H1 2026	Q3 2026	9M 2026
Amplification	47.2	45.4	92.6	46.3	138.9
Detection & Imaging	16.2	21.1	37.2	18.6	55.9
Eliminations & Other	0.1	0.0	0.1	0.1	0.2
Adjusted gross margin	63.5	66.4	129.9	65.0	194.9
As a % of total revenue	51.8%	50.9%	51.3%	48.6%	50.4%

Quarterly figures for 9M 2025

In € millions	Q1 2025	Q2 2025	H1 2025	Q3 2025	9M 2025
Amplification	79.1	78.8	157.9	73.9	231.8
Detection & Imaging	24.0	38.3	62.3	34.7	97.0
Eliminations & Other	(0.7)	0.0	(0.7)	(0.2)	(0.9)
Total revenue	102.4	117.1	219.5	108.3	327.8

In € millions	Q1 2025	Q2 2025	H1 2025	Q3 2025	9M 2025
Amplification	41.1	40.2	81.2	40.5	121.8
Detection & Imaging	11.8	18.5	30.3	15.8	46.1
Eliminations & Other	0.0	0.0	(0.1)	0.1	0.1
Adjusted gross margin	52.9	58.6	111.5	56.5	168.0
As a % of total revenue	51.6%	50.1%	50.8%	52.1%	51.2%

Definitions

Like-for-like growth is defined as the revenue growth achieved by the Group, excluding currency effects and changes in the scope of consolidation. It corresponds to the revenue generated in period “n” by all companies included in the Group’s scope of consolidation at the end of period “n-1” (excluding any contribution from companies acquired since the end of period “n-1”), compared with the revenue generated in period “n-1” by the same companies. Accordingly, like-for-like growth for the nine-month period ended 30 September 2026 excludes the contributions of Noxant, NVLS, Phasics and Emberion, which were acquired by the Group in March 2025, July 2025, October 2025 and April 2026, respectively.

Adjusted gross margin is defined as the difference between the selling price and the cost of products and services (including employee benefits expense).

Adjusted EBITDA is defined as operating profit, excluding (i) depreciation, amortization and impairment losses on non-current assets, net of reversals; (ii) non-recurring income and expenses, as presented in the Group’s consolidated income statement under “Other income” and “Other expenses”; and (iii) items that do not reflect the Group’s ordinary operating performance (in particular, business reorganization and adaptation costs, costs relating to acquisitions and external growth transactions, as well as IFRS 2 share-based payment expense).

Forward-looking statements

Certain information included in this press release does not relate to historical facts but constitutes forward-looking statements. These forward-looking statements are based on current beliefs, expectations and assumptions, including, without limitation, assumptions regarding present and future business strategies and the environment in which Exosens operates, and involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed in or implied by the forward-looking statements included in this press release. These risks and uncertainties include those set out and detailed in Chapter 4 “Risk factors and risk management system” of the Universal Registration Document filed on 9 March 2026 with the French financial markets authority (Autorité des marchés financiers – AMF) under number D.26-0072. Forward-looking statements speak only as of the date of this press release, and the Group expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements included in this press release to reflect any change in expectations or any change in events, conditions or circumstances on which these forward-looking statements are based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Group. Actual results could differ materially from those expressed in, or implied or projected by, forward-looking information and statements. This press release is provided for information purposes only. It does not constitute, and should not be deemed to constitute, an offer of securities to the public.

---

1 Like-for-like.

Attachment

• Exosens_Press Release_9M 2026_VA_FINAL

• The cobas smart e immunoanalyser – the newest addition to Roche’s industry-leading cobas immunoassay systems portfolio – is engineered to deliver central-lab performance in a footprint under one square metre. 
• With a planned menu of over 100 high-medical-value assays, and reaction times of 18 minutes or less for more than 90% of tests, the platform allows smaller laboratories to bring testing in-house, reducing turnaround times for patients.^1,2,3
• The cobas smart e uses the same reagents and Elecsys®  technology as Roche’s high-throughput platforms, optimising patient management with consistent test results over time and across different locations.

Basel, 27 October 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received the CE Mark for its cobas smart e immunoanalyser, a compact, standalone platform engineered to deliver reliable testing with a planned menu of over 100 high-medical-value assays.^1,2 As the latest offering in Roche’s industry-leading cobas immunoassay systems portfolio, the platform bridges critical operational gaps across health systems by fitting central-laboratory precision into a footprint under one square meter. This enables decentralised sites to manage diverse testing demands directly in-house. With reaction times of 18 minutes or less across more than 90% of Roche immunoassays, local facilities can help reduce diagnostic turnaround times.^1,2

“For smaller hospitals and laboratories, maintaining central-lab quality has traditionally meant outsourcing tests,” said Matt Sause, CEO of Roche Diagnostics. “The cobas smart e immunoanalyser fits on a benchtop, bringing Roche’s immunoassay standards directly into these care settings. This means our cobas®  immunoassay solutions now span the full range of healthcare settings while delivering consistent high-quality results,  ensuring patients get timely, accurate answers, no matter where they live.”

The cobas smart e immunoanalyser joins the cobas®  e 402 and cobas®  e 801 analytical units, which run up to 60, 120 and 300 tests an hour respectively. Together, they scale from small local clinics to the highest-volume hospital laboratories, using the same universal reagents and Elecsys® technology, which helps ensure comparability of clinical results.

Across global healthcare systems, acute workforce shortages continue to strain diagnostic delivery, as health systems confront a projected global shortfall of 11 million health workers by 2030.⁴ The cobas smart e immunoanalyser combines minimal maintenance with guided, step-by-step tasks to simplify workflows and improve the productivity of lab personnel while also supporting the delivery of better patient care. Requiring just one single minute of daily operator intervention, the system reduces hands-on maintenance efforts by up to two-thirds compared to previous-generation platforms.^1,2

In addition to easing staffing pressures, the platform is engineered to withstand challenging physical and environmental conditions that often limit testing in decentralised settings. Equipped with an integrated water tank, standard power compatibility and a dust-protection design, the utility-independent engineering of the cobas smart e immunoanalyser bypasses traditional infrastructural barriers, enabling uninterrupted service across rural and resource-constrained clinics.^1,2

Featuring an expansive planned menu of over 100 high-medical-value assays across critical disease areas — including cardiometabolic, oncology and infectious diseases — the cobas smart e immunoanalyser enables low-volume labs to bring essential testing in-house, reducing the delay and cost of sending samples out.^1,2,3 Furthermore, because it utilises the same universal reagent carriers and Elecsys® technology as Roche’s high-throughput central laboratory platforms, it ensures comparability of clinical results across an entire hub-and-spoke network.^1,2

For more information, visit the Roche booth at the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Conference in New Delhi, India from 25 – 29 October 2026.

About the cobas smart e immunoanalyser
The cobas smart e immunoanalyser is the newest member of the cobas immunoassay testing family. It holds 36 reagent positions on a compact benchtop footprint of ~0.9 m² with a planned menu of over 100 assays, across a wide range of disease areas which will be launched in sequential waves.^1,2,3 Designed to support customers focused on maximising efficiency for their time, space and their teams, the cobas smart e immunoanalyser has a high uptime while requiring less hands-on time, with up to 2 hours of walk-away time on a load of 36 samples.^1,2 The possible immunoassay reaction time for routine and emergency samples are the lowest available on the central laboratory market, with a reaction time of 18 minutes or less for routine testing.^1,2 This new immunoanalyser complements cobas e 801 and cobas e 402 analytical units for immunoassay testing as it uses the same reagent packs, system reagents and well-established Elecsys technology. For more information, visit cobas.com.

To find out more about Roche’s cobas® smart e immunoanalyser, click here

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] cobas® smart e analyzer user guide – pre-launch version 0.1 – data on file
[2] Ref-13688 cobas e 411 Operator Manual V 3.3.1
[3} Ref: SWA assay menu and reagent specifications analysis | Data on file | Source: Reagent method sheets.
[4] World Health Organization. Health workforce. https://www.who.int/health-topics/health-workforce#tab=tab_1  (Accessed August 2026).

Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com

Tristan Schmitz Phone: +41 79 529 70 35	Nathalie Altermatt Phone: +41 79 771 05 25
Lorena Corfas Phone: +41 79 568 24 95	Simon Goldsborough Phone: +44 797 32 72 915
Karsten Kleine Phone: +41 79 461 86 83	Kirti Pandey Phone: +41 79 398 38 53
Yvette Petillon Phone: +41 79 961 92 50	Irène Stephan Phone:  +41 79 377 83 75
Albert Thottiyil Phone: +41 79 775 66 12

Roche Investor Relations

Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

Attachment

• Media&Investor Release CE Mark for cobas smart e English

Building on established clinical evidence, Dari-Dream is designed to further characterize the impact of QUVIVIQ on daytime functioning and support its inclusion in the US prescribing information.

Allschwil, Switzerland – October 27, 2026
Idorsia Ltd (SIX: IDIA) announced that the first patients are enrolled in Dari-Dream, a US label-enabling study evaluating QUVIVIQ^® (daridorexant) 50 mg in adults and elderly people with insomnia disorder.

Insomnia disorder is a chronic, 24-hour condition that impacts not only sleep at night but also how people feel and function during the day. Beyond difficulties falling or staying asleep, people with insomnia experience symptoms that affect alertness, cognition, mood, energy, and daily functioning.

QUVIVIQ is supported by an extensive body of clinical evidence demonstrating not only benefits across nighttime symptoms of insomnia, but also daytime functioning. In the Phase 3 program, meaningful improvement with the 50 mg dose was observed across all three IDSIQ domains of alert/cognition, mood, and sleepiness as well as the overall IDSIQ score. These findings are reflected in prescribing information in multiple countries worldwide, including across Europe.

Following discussions with the US Food and Drug Administration, Dari-Dream has been specifically designed to further characterize these outcomes and support their inclusion in US prescribing information. Inclusion of daytime functioning information in the US label would support broader physician and patient education on an aspect of insomnia treatment that is highly relevant to people living with the disorder.

Amer Joseph, MD, Chief Medical Officer and Head of Global Clinical Development at Idorsia commented:
“Insomnia is a 24-hour condition that affects patients both during the night and throughout the following day. Daridorexant was specifically designed to provide efficacy across the night while minimizing next-morning residual sleepiness. Importantly, its differentiated profile as an equipotent dual orexin receptor antagonist may also contribute directly to improvements in daytime functioning. Building on the extensive evidence generated during the clinical development program, Dari-Dream is designed to further characterize these outcomes and support their inclusion in US prescribing information.”

Roland Wandeler, Chief Executive Officer of Idorsia, commented:
“For people living with insomnia, the burden of the condition extends well beyond the night. Difficulties with alertness, mood, energy, and daily functioning can affect many aspects of everyday life. We have already generated compelling evidence demonstrating the benefits of daridorexant not only on sleep, but also daytime functioning. Dari-Dream is an important next step in our efforts to make this information available to healthcare professionals and patients in the US. Together with other initiatives aimed at enhancing the patient and physician experience, Dari-Dream forms part of our broader strategy to maximize the potential of QUVIVIQ for patients.”

About Dari-Dream (NCT07843329)
Dari-Dream is a Phase 3, randomized, double-blind, placebo-controlled study evaluating QUVIVIQ (daridorexant) 50 mg in adults and elderly people with insomnia disorder. Approximately 344 participants will be randomized to receive daridorexant 50 mg or placebo once nightly for three months. The study will evaluate changes in subjective total sleep time as its primary endpoint. Key secondary endpoints include the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) sleepiness domain and total score, assessing the physical, emotional, and cognitive consequences of insomnia during the day. Results are expected during 2028.

Notes to the editor

QUVIVIQ – a different kind of insomnia treatment
Insomnia affects millions worldwide, yet commonly used treatments can lead to next-day drowsiness, dependence, and withdrawal symptoms – leaving a clear unmet need for safer, effective alternatives.

Discovered by Idorsia, QUVIVIQ works differently from traditional hypnotics. As a dual orexin receptor antagonist, it selectively targets the orexin system, helping to regulate overactive wake signaling without broadly suppressing brain activity. Its optimized pharmacokinetics promote restorative sleep throughout the entire night, reducing morning sleepiness, and improving daytime functioning.

Clinical trials published in The Lancet Neurology demonstrated that daridorexant significantly improved sleep onset, sleep maintenance, and self-reported total sleep time at 25mg and 50mg doses compared to placebo. Daridorexant 50 mg also demonstrated a highly significant improvement in daytime functioning compared to placebo, findings that are reflected in prescribing information in multiple countries worldwide.

Idorsia is building QUVIVIQ into a global brand
QUVIVIQ is marketed by Idorsia in North America and Europe, and is available in key international markets in Asia-Pacific and the Middle East through commercial partnerships. Idorsia also has a license and supply agreement for Latin America.

IDSIQ^© 2020, University of Pittsburg. All rights reserved. IDSIQ-14 derivative created 2020 by Idorsia Pharmaceuticals Ltd under license and distributed by Idorsia Pharmaceuticals Ltd under license. IDSIQ is further a registered trademark of Idorsia Pharmaceuticals Ltd.

About Idorsia
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).

For further information, please contact:
Investor & Media Relations
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com

The above information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “intend”, “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Idorsia has transferred its rights for aprocitentan, cenerimod and selatogrel to Idorsia Investments SARL to allow the repayment of notes issued in connection with the repurchase offer completed in August 2025. More details on the transfer can be found in the current Financial Report.

Attachment

• Press Release PDF

AS LHV Group has decided the company’s financial calendar for the 2027 financial year.

In 2027 LHV Group plans to disclose information and organise the Annual General Meeting of shareholders according to the following schedule:

09.02.2027	Q4 2026 and unaudited full year results
16.02.2027	Disclosure of Financial Plan
16.02.2027	January results
09.03.2027	Audited results for 2026
16.03.2027	February results
31.03.2027	Annual General Meeting
20.04.2027	Q1 interim results
11.05.2027	April results
15.06.2027	May results
20.07.2027	Q2 interim results
10.08.2027	July results
14.09.2027	August results
19.10.2027	Q3 interim results
16.11.2027	October results
14.12.2027	November results

 
LHV Group is the largest domestic financial group and capital provider in Estonia. LHV Group’s key subsidiaries are LHV Pank, LHV Varahaldus, LHV Kindlustus and LHV Bank Limited. The Group employs approximately 1,200 people. The services of LHV Pank are used by over 517,000 customers, the II pillar pension funds managed by LHV have 104,000 active customers and LHV Kindlustus protects a total of 246,000 customers. LHV Bank Limited, a subsidiary of the Group, holds a banking licence in the United Kingdom and provides banking services to international financial technology companies, as well as loans to small and medium-sized enterprises. 

Investor Relations 
Sten Hans Jakobsoo 
Head of Investor Relations and Corporate Development 
Email: stenhans.jakobsoo@lhv.ee 

Communications 
Paul Pihlak 
Head of Communications 
Email: paul.pihlak@lhv.ee